Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.85 |
| ▸ | SRC | P12931 | 6/20 | 0.70 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2843055 | 0.99 | EGFR (0.83) | EGFRERBB2SRCMAP2K1 | |
| Hydrochloric Acid SCHEMBL2840495 | 0.99 | EGFR (0.83) | EGFRERBB2SRCMAP2K1 | |
| SCHEMBL5106023 | 0.92 | EGFR (1.00) | EGFRERBB2SRCMAP2K1 | |
| SCHEMBL2574073 | 0.90 | EGFR (0.85) | EGFRERBB2SRCMAP2K1 | |
| SCHEMBL3600034 | 0.90 | EGFR (0.72) | EGFRERBB2SRC | |
| SCHEMBL27728120 | 0.90 | EGFR (0.71) | EGFRERBB2SRC | |
| Hydrochloric Acid SCHEMBL2052299 | 0.90 | EGFR (0.84) | EGFRERBB2SRCMAP2K1 | |
| SCHEMBL12094750 | 0.89 | EGFR (0.67) | EGFRERBB2SRCMAP2K1 | |
| SCHEMBL27728124 | 0.89 | EGFR (0.69) | EGFRERBB2SRC | |
| SCHEMBL1897299 | 0.88 | EGFR (0.67) | EGFRERBB2SRCMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253620-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2010-11-24 | — | — | EP | claimed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | claimed |
| EP-1950201-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2008-07-30 | — | — | EP | claimed |
| EP-1263503-B1 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | WYETH CORP (US) | 2005-11-02 | — | — | EP | claimed |
| EP-0973746-B1 | SUBSTITUTED 3-CYANO QUINOLINES | WYETH CORP (US) | 2003-09-24 | — | — | EP | claimed |
| JP-2003526686-A | — | — | 2003-09-09 | — | — | JP | claimed |
| EP-1263503-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2002-12-11 | — | — | EP | claimed |
| US-6384051-B1 | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2002-05-07 | — | — | US | claimed |
| WO-2001068186-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2001-09-20 | — | — | WO | claimed |
| EP-1117649-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018740-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| EP-0973746-A1 | SUBSTITUTED 3-CYANO QUINOLINES | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | claimed |
| US-6002008-A | Substituted 3-cyano quinolines | AMERICAN CYANAMID COMPANY | 1999-12-14 | — | — | US | claimed |
| WO-1998043960-A1 | SUBSTITUTED 3-CYANO QUINOLINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-08 | — | — | WO | claimed |
| CN-103987700-B | 4-quinazoline amine derivant and application thereof | 江苏豪森药业集团有限公司 | 2016-08-31 | — | — | CN | disclosed |
| EP-2896612-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| EP-0973746-A1 | SUBSTITUTED 3-CYANO QUINOLINES | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | disclosed |
| US-6002008-A | Substituted 3-cyano quinolines | AMERICAN CYANAMID COMPANY | 1999-12-14 | — | — | US | disclosed |
| WO-1998043960-A1 | SUBSTITUTED 3-CYANO QUINOLINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885ERBB2 170/4885SRC 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.